Remove Communication Remove Definition Remove Insurance Coverage and Processing
article thumbnail

Towards a healthier, more equitable and innovative Indian healthcare sector

Express Pharma

Specific highlights of the budget for the sector include an increase in outlay for research and development and for the Ayushman BharatPradhan Mantri Jan Arogya Yojana (PM-JAY), the government’s universal health coverage scheme, which saw a 10 per cent budget increase to Rs 7,300 crores.

article thumbnail

NHC Submits Comments on CMS’ Proposed Rule on Marketplace Integrity and Affordability

Putting Patients First Blog

Other members include health-related associations and nonprofit organizations including the provider, research, and family caregiver communities; and businesses and organizations representing biopharmaceuticals, devices, diagnostics, generics, and payers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture

Pharmaceutical Technology

By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

Pharmaceutical Commerce

I'll explain why this "gold rush" is fraught with peril, from a risk management and insurance perspective. Compounding, by definition, involves customizing medications to meet individual patient needs, such as altering dosage forms or removing allergens. So, why aren't compounded GLP-1s approved?

article thumbnail

Sarepta allowed to continue US Elevidys shipments

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Despite being a different drug, it is built on the same viral vector as Elevidys, a recombinant adeno-associated viral vector (AAV) called AAVrh74.

article thumbnail

Prasad’s FDA exit may accelerate cell and gene therapy approvals

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. His exit raises critical questions: which evidence standards will prevail: traditional or accelerated?” Sign up for our daily news round-up!

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

We believe that patient-centric engagement is essential to ensure that the negotiation process leads to outcomes that genuinely benefit patients. Patient Engagement The NHC recognizes and commends CMS’ willingness to improve the listening sessions and the data submission processes. Improving the Data Collection (ICR) Process.